Type 5 phosphodiesterase inhibition by sildenafil abrogates acute smoking-induced endothelial dysfunction | Zendy

Charalambos Vlachopoulos | Zendy; Dorothea Tsekoura | Zendy; Nikolaos Alexopoulos | Zendy; Demosthenes B. Panagiotakos | Zendy; K. Aznaouridis | Zendy; Christodoulos Stefanadis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Type 5 phosphodiesterase inhibition by sildenafil abrogates acute smoking-induced endothelial dysfunction

Author(s) -

Charalambos Vlachopoulos,

Dorothea Tsekoura,

Nikolaos Alexopoulos,

Demosthenes B. Panagiotakos,

K. Aznaouridis,

Christodoulos Stefanadis

Publication year - 2004

Publication title -

american journal of hypertension

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 1.009

H-Index - 136

eISSN - 1941-7225

pISSN - 0895-7061

DOI - 10.1016/j.amjhyper.2004.06.027

Subject(s) - medicine , sildenafil , phosphodiesterase , cgmp specific phosphodiesterase type 5 , endothelial dysfunction , pharmacology , erectile dysfunction , enzyme , biochemistry , chemistry

Endothelial dysfunction is a key early event in the process of atherosclerosis and a risk factor for cardiovascular events. Sildenafil, an effective oral treatment for patients with erectile dysfunction, inhibits cGMP degradation by specific type 5 phosphodiesterase (PDE) inhibition. Sildenafil has been shown to improve vascular function, however, the effect of type 5 PDE inhibition on acute smoking-induced endothelial dysfunction is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research